Invida is expected to be in charge of filing and commercialising the drugs in different countries. The agreement is for an initial period of five years renewable for an additional period of five years, and covers Singapore, Malaysia, Philippines, Indonesia, Thailand and India, with the exception of Diphereline for Thailand.
In the context of the agreement, Ipsen is expected to receive payments upon achievement by Invida of certain commercial milestones.
Christophe Jean, executive vice president and chief operating officer of Ipsen, said: “We are very pleased to partner with Invida that will optimise time-to-market in the region while allowing us to work with a single, trusted partner.
“This agreement contributes to expand the geographical reach of Ipsen’s specialty care portfolio in the Asia Pacific region and give physicians and patients access to innovative treatments in severe conditions in oncology and endocrinology.”
John Graham, CEO of Invida Group, said: “This partnership is an excellent opportunity for Invida to expand its specialty care offerings in the region, a segment which we feel possesses immense potential for Invida as the demand grows throughout Asia.
“We are thrilled to partner with Ipsen, as both our companies are strongly focused on bringing innovative products to market. We feel that by introducing Ipsen’s drugs into these countries, we will be able to improve the lives of patients while advancing the standard of care for these important indications.
“This partnership will allow Ipsen to leverage Invida’s local expertise, proven methodology, and market insights to commercialise these products to a wide audience throughout Asia.”